Notable studies

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

This page lists published ME/CFS studies that are notable, for particularly interesting findings, for controversial findings, or for their quality or their size.

Studies[edit | edit source]

General category Year Study title & Author(s) Notes Cohort size Blinded (double, single, not)
Epidemiological 2015 Institute of Medicine report Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness
Ellen Wright Clayton (Chair), Margarita Alegría, Lucinda Bateman, Lily Chu, Charles Cleeland, Ronald Davis, Betty Diamond, Theodore Ganiats, Betsy Keller, Nancy Klimas, A Martin Lerner, Cynthia Mulrow, Benjamin Natelson, Peter Rowe, Michael Shelanski
Epidemiological 2015 Pathways to prevention report
Green CR, Cowan P, Elk R, O'Neil KM, Rasmussen AL
Epidemiological 2014 Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012
Bakken IJ, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trogstad L, Håberg SE, Magnus P
Epidemiological 2013 The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis
Johnston S, Brenu EW, Staines D, Marshall-Gradisnik SM
Epidemiological 2011 Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care
Luis Nacul, Eliana Lacerda, Derek Pheby, Peter Campion, Mariam Molokhia, Shagufta Fayyaz, Jose CDC Leite, Fiona Poland, Amanda Howe, Maria L Drachler
Epidemiological 2007 The burden of disease and injury in Australia 2003
Begg S, Vos T, Barker B, Stevenson C, Stanley L, Lopez A
Epidemiological 2006 Prolonged Illness after infectious mononucleosis is associated with altered immunity but not with increased viral load
Cameron B, Bharadwaj M, Burrows J, Fazou C, Wakefield D, Hickie I, Ffrench R, Khanna R and Lloyd A
See also Model of Post Infective Fatigue Forming: the Dubbo Studies
Epidemiological 2006 Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus
Vernon S, Whistler T, Cameron B, Hickie I, Reeves WC and Lloyd A
See also Model of Post Infective Fatigue Forming: the Dubbo Studies
Epidemiological 2006 Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study
Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC, Lloyd A
Epidemiological 2005 A systematic review describing the prognosis of chronic fatigue syndrome
Ruth Cairns, Matthew Hotopf
Epidemiological 1996 Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups
Komaroff AL, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, Kornish RJ 2nd, Ware NC, Ware JE Jr, Bates DW
Immunological 2019 A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Rahim Esfandyarpour, Alex Kashi, Mohsen Nemat-Gorgani, Julie Wilhelmy, and Ron W. Davis |
Immunological 2015 Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome
Landi A, Broadhurst D, Vernon SD, Tyrrell DL, Houghton M
Immunological 2015 Distinct plasma immune signatures in ME/CFS are present early in the course of illness
Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, Peterson DL, Gottschalk CG, Schultz AF, Che X, Eddy ML, Komaroff AL, Lipkin WI
Immunological 2014 Deficient EBV-specific B-and T-cell response in patients with chronic fatigue syndrome
Madlen Loebel, Kristin Strohschein, Carolin Giannini, Uwe Koelsch, Sandra Bauer, Cornelia Doebis, Sybill Thomas, Nadine Unterwalder, Volker von Baehr, Petra Reinke, Michael Knops, Leif G. Hanitsch, Christian Meisel, Hans-Dieter Volk, Carmen Scheibenbogen
Immunological 2012 Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis
Ekua Brenu, Mieke L van Driel, Donald Staines, Kevin J Ashton, Sharni L Hardcastle, James Keane, Lotti Tajouri, Daniel Peterson, Sandra B Ramos, Sonya Marshall-Gradisnik
Immunological 2011 Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study
Øystein Fluge , Ove Bruland, Kristin Risa, Anette Storstein, Einar K. Kristoffersen, Dipak Sapkota, Halvor Næss, Olav Dahl, Harald Nyland, Olav Mella
Immunological 2010 Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26
Fletcher MA, Zeng XR, Maher K
Immunological 2008 Neuroendocrine and immune network remodeling in chronic fatigue syndrome: an exploratory analysis
Fuite J, Suzanne Vernon, Gordon Broderick
Immunological 2008 Cytokine Polymorphisms Have a Synergistic Effect on Severity of the Acute Sickness Response to Infection
Vollmer-Conna U, Piraino B, Cameron B
Immunological 2007 Postinfective fatigue syndrome is not associated with altered cytokine production
Vollmer-Conna U, Cameron B, Pavlovic D
Immunological 2006 A first study of cytokine genomic polymorphisms in CFS: positive association of TNF‐857 and IFNgamma 874 rare alleles
Carlo‐Stella N, Badulli C, De S
Immunological 2005 Association of chronic fatigue syndrome with human leucocyte antigen class II alleles
Smith J, Fritz EL, Jonathan Kerr
Metabolic 2016 Metabolic features of chronic fatigue syndrome
Ronald Davis (Editor), Robert Naviaux, Jane C. Naviaux, Kefeng Li, A. Taylor Bright, William A. Alaynick, Lin Wang, Asha Baxter, Neil Nathan, Wayne Anderson, Eric Gordon
Metabolomics showed that chronic fatigue syndrome is a highly concerted hypometabolic response to environmental stress that traces to mitochondria and was similar to the classically studied developmental state of dauer.
Metabolic 2014 Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO2peak indicates functional impairment
Betsy Keller, John Pryor, Ludovic Giloteaux
Metabolic 2012 Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls
AT White, Alan Light, RW Hughen, TA Vanhaitsma, Kathleen Light
Metabolic 2009 Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects
Alan Light, AT White, RW Hughen, Kathleen Light
Neurological 2016 Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study.
Shan ZY, Kwiatek R, Burnet R, Del Fante P, Staines DR, Marshall-Gradisnik SM, Barnden LR
Neurological 2015 Phase relationships are only measurable by the qEEG, giving us a unique window into the ME disease process
Marcie Zinn, Mark Zinn, Leonard Jason
See also Phase Reset of the Default Mode Network.
Neurological 2015 There is poor agreement among researchers and clinicians about case definitions. Key domains are discussed.
Leonard Jason, Marcie Zinn, Mark Zinn
See also Lack of Agreement in Case Definitions hampers research.
Neurological 2015 Right arcuate fasciculus abnormality in chronic fatigue syndrome
Michael Zeineh, Kang J, Atlas SW, Raman MM, Reiss AL, Jane Norris, Valencia I, Jose Montoya
Neurological 2007 Symptoms of autonomic dysfunction in chronic fatigue syndrome
Julia Newton, O Okonkwo, K Sutcliffe, Seth A, Shin J, Jones DE
Treatment 2015 Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome
Øystein Fluge, Olav Mella, Madlen Loebel, Patricia Grabowski, Heidecke H, Bauer S, Hanitsch LG, Wittke K, Meisel C, Reinke P, Volk HD, Carmen Scheibenbogen
Treatment 2015 B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment
Øystein Fluge, Olav Mella, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, Kristoffersen EK, Sørland K, Bruland O, Dahl O
Treatment 2013 Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls
Amolak Bansal, AS Bradley, B Ford
Treatment 2013 Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study
Jarred Younger, Sean Mackey
Treatment 2012 The GI Microbiome and its Role in Chronic Fatigue Syndrome: A Summary of Bacteriotherapy
Thomas Borody, Anna Nowak, Sarah Finalayson
Treatment 2011 Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study
Øystein Fluge, Olav Mella, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H
Treatment 2010 Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels
Jarred Younger, Noor N, McCue R, Mackey S
Treatment 2009 Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
Øystein Fluge, Olav Mella
Treatment 2008 Normalization of leaky gut in Chronic Fatigue Syndrome (CFS) is accompanied by a clinical improvement
Michael Maes, Jean-Claude Leunis
Psychological 2011 The PACE trial
Peter White, Kimberly A Goldsmith, AL Johnson, L Potts, Rebecca Walwyn, Julia C DeCesare, Hannah L Baber, Mary Burgess, Lucy V Clark, Diane L Cox, Jessica Bavinton, BJ Angus, Gabrielle Murphy, Maurice Murphy, Hazel O'Dowd, David Wilks, P McCrone, Trudie Chalder, Michael Sharpe
Psychological 2005 The Placebo Response in the Treatment of Chronic Fatigue Syndrome: A Systematic Review and Meta-Analysis
Hyong Jin Cho, Matthew Hotopf, Simon Wessely
Found that the placebo response was actually lower in CFS patients
Psychological 2014 Exercise therapy for chronic fatigue syndrome
Cochrane review: Lillebeth Larun, Kjetil G. Brurberg, Jan Odgaard-Jensen, Jonathan R Price

See also[edit | edit source]

Learn more[edit | edit source]

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

creatine (CR) - A natural substance that turns into creatine phosphate in the body, which helps make ATP. ATP provides the energy for muscles Often taken as a supplement to improve sports performance. (Learn more:

Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.

metabolomics The analysis of the chemical metabolism within cells, tissues or organisms. The term is often used to refer to the full set of metabolites found in a cell in a given environment.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.